Tikvah Management’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Tikvah Management’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,561	Closed	-$205K	–	25
2024 Q4	$205K	Hold	10,561	–	–	0.06%	24
2024 Q3	$165K	Hold	10,561	–	–	0.05%	24
2024 Q2	$89.2K	Sell	10,561 -1	-0%	-$12	0.03%	25
2024 Q1	$163K	Hold	10,562	–	–	0.05%	23
2023 Q4	$146K	Hold	10,562	–	–	0.05%	22
2023 Q3	$121K	Hold	10,562	–	–	0.04%	22
2023 Q2	$263K	Hold	10,562	–	–	0.09%	22
2023 Q1	$383K	Hold	10,562	–	–	0.16%	21
2022 Q4	$637K	Sell	10,562 -33,333	-76%	-$2.23M	0.3%	21
2022 Q3	$3.29M	Hold	43,895	–	–	1.52%	15
2022 Q2	$5.03M	Buy	43,895 +20,308	+86%	+$2.38M	2.17%	11
2022 Q1	$4.46M	Buy	+23,587	New	+$5.46M	1.43%	16

Tikvah Management's OMIC Position: Q1 2025 in Review

Tikvah Management sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 10,561 shares — an estimated $205K sold.

Tikvah Management first reported a position in OMIC in Q1 2022 and held it in 12 quarters. The position peaked at $5.03M in Q2 2022. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.

Tikvah Management reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Tikvah Management sold 10,561 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $205K.
Tikvah Management first reported a position in Singular Genomics Systems, Inc. Common Stock in Q1 2022 and held it in 12 quarters.
Tikvah Management's Singular Genomics Systems, Inc. Common Stock position peaked at $5.03M in Q2 2022.
0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.

Based on Tikvah Management's 13F filing for Q1 2025, filed 13 May 2025.